TYPTF (Tryptamine Therapeutics) Beginning Cash Position : $3.40 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Tryptamine Therapeutics Beginning Cash Position?

Tryptamine Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2024 was $3.40 Mil.

Tryptamine Therapeutics's quarterly Beginning Cash Position declined from Jun. 2023 ($1.13 Mil) to Dec. 2023 ($1.10 Mil) but then increased from Dec. 2023 ($1.10 Mil) to Dec. 2024 ($3.40 Mil).

Tryptamine Therapeutics's annual Beginning Cash Position increased from Jun. 2021 ($1.33 Mil) to Jun. 2022 ($8.94 Mil) but then declined from Jun. 2022 ($8.94 Mil) to Jun. 2023 ($3.25 Mil).

Tryptamine Therapeutics Beginning Cash Position Historical Data

The historical data trend for Tryptamine Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Beginning Cash Position Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Beginning Cash Position

Get a 7-Day Free Trial

0.04

3.05

1.33

8.94

3.25

Tryptamine Therapeutics Semi-Annual Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
Beginning Cash Position	Get a 7-Day Free Trial								6.58	3.27	1.13	1.10	3.40

Tryptamine Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Tryptamine Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

TYP:Australia

Address

C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.tryptherapeutics.com

Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

From GuruFocus

Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines

By PRNewswire PRNewswire • 12-22-2021

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

By PRNewswire PRNewswire • 01-31-2022